Company: MIRA
Filing Date: 2025-08-08
Form Type: DEFM14A
Source: 0001641172-25-022816
Chunk: 98

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-08-08
Form: DEFM14A
Chunk 98
---
     |            |       - |    |     |                |   258,900 |     |                                 | - |     |                                | - |     |                        | 26,902 | -5 |     |       |   444,021 |
| CFO                    |     | 2023 |     |        | 165,000 |     |       |  88,475 | -4 |     |            |       - |    |     |                |   282,215 |     |                                 | - |     |                                | - |     |                        |  5,934 | -5 |     |       |   541,624 |

| (1) | The                                                                                                                                     
 amounts represent bonus earned as part of CEO Executive Scorecard                                                                       |
| (2) | On                                                                                                                                      
 December 6, 2024, Mr. Aminov was awarded an RSU Stock Award                                                                             |
| (3) | Amount                                                                                                                                  
 represents health insurance premiums paid, car payments, car insurance, and club memberships                                            |
| (4) | Amount                                                                                                                                  
 represents IPO bonus paid                                                                                                               |
| (5) | Amounts                                                                                                                                 
 represent health insurance premiums paid                                                                                                |
| (6) | The                                                                                                                                     
 reported amounts represent the aggregate grant date fair value of the awards computed in accordance with Financial Accounting Standards 
 Board Account Standards Codification Topic 718, Stock Compensation, as modified or supplemented, or FASB ASC Topic 718. The assumptions 
 used in calculating the grant date fair value of the stock options reported in this column are set forth in Note 8 to our Consolidated  
 Financial Statements for the year ended December 31, 2024 included in the Company’s Form 10-K filed for the fiscal year ended           
 December 31, 2024.                                                                                                                      |
| (7) | Ms.                                                                                                                                     
 Yanez resigned as the Company’s CFO on May 16, 2025.                                                                                    |

| 54 |

Narrative Disclosure to Summary Compensation Table

Employment Agreements

Except as set forth below, we currently have no written employment agreements with any of our named executive officers.

Erez Aminov

Effective April 28, 2023, we entered into an employment agreement with Mr. Aminov, as amended on August 28, 2023, pursuant to which Mr. Aminov will serve as our Chief Executive Officer. Under his employment agreement, as amended, Mr. Aminov has agreed to devote at least